Off-the-Shelf Immunotherapy ADXS-504 Under Evaluation in Biochemically Recurrent Prostate Cancer
May 12th 2021Columbia University Irving Medical Center will partner with Advaxis, Inc. to fund a phase 1 clinical trial that seeks to examine the novel off-the-shelf neoantigen immunotherapy agent ADXS-504 in patients with biochemically recurrent prostate cancer.
Next-Generation Tissue Factor–Targeting ADC XB002 to be Examined in Several Solid Tumors
May 12th 2021The safety, tolerability, pharmacokinetics, and preliminary antitumor activity of the novel agent XB002 is set to be examined in an upcoming phase 1 clinical trial that is expected to begin the second quarter of 2021.
Glofitamab Demonstrates Durable Responses in Relapsed/Refractory B-Cell Lymphoma
April 21st 2021The novel T-cell–engaging bispecific antibody glofitamab demonstrated encouraging clinical activity, with frequent and durable complete remissions, and a manageable toxicity profile in patients with predominantly refractory, aggressive B-cell lymphoma.